Over the past 12 months, 3 insiders at Taysha Gene Therapies, Inc. filed 14 open-market SEC Form 4 transactions on TSHA: 0 purchases worth $0 and 14 sales worth $6.7M. Insiders have been net sellers over this period. The most recent filing was on Jul 10, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 10, 26 | Sukumar NagendranPresident and Head of R&D | SELL | 200.0K | $6.24 | $1.2M |
| Feb 4, 26 | Kamran AlamCHIEF FINANCIAL OFFICER | SELL | 1.7K | $4.52 | $7K |
| Jan 26, 26 | Kamran AlamCHIEF FINANCIAL OFFICER | SELL | 23.8K | $4.61 | $110K |
| Jan 26, 26 | Sukumar NagendranPresident and Head of R&D | SELL | 26.9K | $4.61 | $124K |
| Jan 26, 26 | Sean P. NolanChief Executive Officer | SELL | 41.3K | $4.61 | $190K |
| Jan 23, 26 | Kamran AlamCHIEF FINANCIAL OFFICER | SELL | 79.0K | $4.75 | $375K |
| Jan 23, 26 | Sukumar NagendranPresident and Head of R&D | SELL | 89.1K | $4.75 | $423K |
| Jan 23, 26 | Sean P. NolanChief Executive Officer | SELL | 136.8K | $4.75 | $650K |
| Jan 12, 26 | Sukumar NagendranPresident and Head of R&D | SELL | 200.0K | $4.71 | $942K |
| Dec 1, 25 | Sukumar NagendranPresident and Head of R&D | SELL | 260.0K | $4.51 | $1.2M |
| Nov 28, 25 | Sukumar NagendranPresident and Head of R&D | SELL | 110.1K | $4.75 | $523K |
| Sep 10, 25 | Sukumar NagendranPresident and Head of R&D | SELL | 200.0K | $3.23 | $646K |
| Aug 21, 25 | Kamran AlamCHIEF FINANCIAL OFFICER | SELL | 54.5K | $2.85 | $155K |
| Aug 21, 25 | Sukumar NagendranPresident and Head of R&D | SELL | 57.1K | $2.85 | $163K |
| May 30, 25 | Paul B ManningTenPercentOwner | BUY | 750.0K | $2.75 | $2.1M |
| Jun 27, 24 | Paul B ManningTenPercentOwner | BUY | 1.33M | $2.25 | $3.0M |
| Nov 17, 23 | Paul B ManningTenPercentOwner | BUY | 100.0K | $1.63 | $163K |
| Aug 24, 23 | Kamran AlamChief Financial Officer | SELL | 33.0K | $2.33 | $77K |
| Aug 16, 23 | Phillip B. DonenbergDirector | BUY | 111.1K | $0.90 | $100K |
| Aug 16, 23 | Paul B ManningTenPercentOwner | BUY | 16.47M | $0.90 | $14.8M |
| Aug 16, 23 | Sean P. NolanChief Executive Officer | BUY | 444.4K | $0.90 | $400K |
| Aug 16, 23 | John A Stalfort IIIDirector | BUY | 388.9K | $0.90 | $350K |
| Jul 13, 23 | R.a. Session IITenPercentOwner | SELL | 5.3K | $0.70 | $4K |
| Jul 12, 23 | R.a. Session IITenPercentOwner | SELL | 80.5K | $0.71 | $57K |
| Jun 23, 23 | R.a. Session IITenPercentOwner | SELL | 18.1K | $0.70 | $13K |
| Jun 22, 23 | R.a. Session IITenPercentOwner | SELL | 10.5K | $0.70 | $7K |
| Jun 21, 23 | R.a. Session IITenPercentOwner | SELL | 139.0K | $0.70 | $97K |
| Jun 20, 23 | R.a. Session IITenPercentOwner | SELL | 295.7K | $0.71 | $210K |
| May 16, 23 | Sukumar NagendranPresident and Head of R&D | BUY | 5.0K | $0.68 | $3K |
| Oct 31, 22 | Paul B ManningDirector,TenPercentOwner | BUY | 1.50M | $2.00 | $3.0M |
| Aug 23, 22 | Kamran AlamChief Financial Officer | SELL | 3.3K | $3.47 | $12K |
| Aug 22, 22 | Kamran AlamChief Financial Officer | SELL | 9.7K | $3.50 | $34K |
| Aug 19, 22 | Kamran AlamChief Financial Officer | SELL | 11.5K | $3.75 | $43K |
| Aug 18, 22 | Kamran AlamChief Financial Officer | SELL | 7.5K | $3.87 | $29K |
| Jul 6, 22 | Suyash PrasadCMO and Head of R&D | SELL | 9.0K | $3.79 | $34K |
| Jul 5, 22 | Suyash PrasadCMO and Head of R&D | SELL | 3.9K | $3.51 | $14K |
| Jul 1, 22 | Suyash PrasadCMO and Head of R&D | SELL | 23.9K | $3.53 | $84K |
| Jun 30, 22 | Suyash PrasadCMO and Head of R&D | SELL | 13.9K | $3.72 | $52K |
| Jun 29, 22 | Suyash PrasadCMO and Head of R&D | SELL | 12.3K | $3.81 | $47K |
| Feb 3, 22 | Paul B ManningDirector,TenPercentOwner | BUY | 50.0K | $7.84 | $392K |
| Feb 2, 22 | Phillip B. DonenbergDirector | BUY | 3.0K | $7.78 | $23K |
| Feb 2, 22 | Paul B ManningDirector,TenPercentOwner | BUY | 58.0K | $7.77 | $451K |
| Feb 2, 22 | Sukumar NagendranDirector | BUY | 10.0K | $8.01 | $80K |
| Nov 24, 21 | Paul B ManningDirector,TenPercentOwner | BUY | 2.2K | $13.19 | $29K |
| Nov 23, 21 | Paul B ManningDirector,TenPercentOwner | BUY | 20.0K | $12.54 | $251K |
| Nov 23, 21 | R.a. Session IIPresident and CEO | BUY | 26.0K | $12.65 | $329K |
| Aug 20, 21 | Kamran AlamChief Financial Officer | SELL | 9.7K | $17.14 | $163K |
| Aug 19, 21 | Kamran AlamChief Financial Officer | SELL | 9.4K | $17.11 | $154K |
| Aug 18, 21 | Kamran AlamChief Financial Officer | SELL | 11.2K | $17.35 | $194K |
Over the past 12 months, insiders at Taysha Gene Therapies, Inc. filed 0 open-market purchases worth $0 and 14 sales worth $6.7M on TSHA, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 10, 26.
The largest recent open-market TSHA insider purchase in our data was $14.8M by Paul B Manning, TenPercentOwner, filed on Aug 16, 23.
3 different insiders at Taysha Gene Therapies, Inc. filed open-market SEC Form 4 transactions on TSHA over the last 12 months.
InsiderTape plots every TSHA insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Taysha Gene Therapies, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →